| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/11/2007 | US20070010529 Nitrogenous heterocyclic compounds and medical use thereof |
| 01/11/2007 | US20070010528 excellent efficacy, oral absorbability, sustained effect, fewer side effects; for thrombosis; anticoagulants; N-(4-((4-( 3-((6-chloro-2-naphthyl)sulfonyl)propanoyl)-1-piperazinyl)methyl)-3-methyl-1,3-thiazol-2(3H)-ylidene)-N-methylamine |
| 01/11/2007 | US20070010527 4-Anilino-3-quinolinecarbonitriles for the treatment of cancer |
| 01/11/2007 | US20070010526 Therapeutic isoquinoline compounds |
| 01/11/2007 | US20070010525 Method and compositions for modulating neuropeptide hormone secretion |
| 01/11/2007 | US20070010524 Azaindazole compounds and methods of use |
| 01/11/2007 | US20070010523 Azaindazole compounds and methods of use |
| 01/11/2007 | US20070010522 Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists |
| 01/11/2007 | US20070010521 Condensed polycyclic compounds |
| 01/11/2007 | US20070010520 Triazolopyrazines and methods of making and using the same |
| 01/11/2007 | US20070010519 New pyridazines as 11B-HSD1 inhibitors |
| 01/11/2007 | US20070010518 Method for administering levosimendan |
| 01/11/2007 | US20070010517 Pharmaceutical salts of reboxetine |
| 01/11/2007 | US20070010516 Novel piperidine derivatives |
| 01/11/2007 | US20070010515 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof |
| 01/11/2007 | US20070010514 Non-steroidal progesterone receptor modulators |
| 01/11/2007 | US20070010513 1-(1-Heteroarylmethyl)piperidin-4-ylcarbonyl)-4-substituted-piperidine derivatives; respiratory allergies, congestion, obesity, metabolic syndrome nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma or cognition deficit disorders |
| 01/11/2007 | US20070010512 Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs |
| 01/11/2007 | US20070010511 Organic compounds |
| 01/11/2007 | US20070010510 4-Substituted derivatives of pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof |
| 01/11/2007 | US20070010509 Cycloamine ccr5 receptor antagonists |
| 01/11/2007 | US20070010508 Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
| 01/11/2007 | US20070010507 Compounds useful in the therapy of alzheimer's disease and formulations containing them |
| 01/11/2007 | US20070010506 Methods of using nitroxides in conjuction with photosensitzers and sonosensitizers |
| 01/11/2007 | US20070010505 Methods of treating disease states using antiangiogenic agents |
| 01/11/2007 | US20070010504 Polymorphic and amorphous salt forms of squalamine dilactate |
| 01/11/2007 | US20070010503 Compounds useful for treating neurodegenerative disorders |
| 01/11/2007 | US20070010502 Synergistic mixture containing pyrimidopyrimidine compound with another active material |
| 01/11/2007 | US20070010501 Skin treatments |
| 01/11/2007 | US20070010500 Contraceptives comprising 21 daily sequential dosages, each having an estrogen, a progestin and a Vitamin D compound, and 7 hormone-free dosage forms; increased apoptosis of ovarian epithelial cells |
| 01/11/2007 | US20070010499 Medicinal compositions containing aspirin |
| 01/11/2007 | US20070010498 Method for reducing blood loss associated with cardio-pulmonary bypass surgery |
| 01/11/2007 | US20070010497 Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| 01/11/2007 | US20070010495 For therapy of asthma, dysmenorrhea, osteoporosis, bone disorders, constipation, renal disorders, sexual dysfunction, baldness, acute hepatitis, bronchitis, burn, chronic obstructive respiratory diseases, Crohn's disease, digestive ulcer, hemophagous syndrome, hepatopathy, hypercytokinemia at dialysis |
| 01/11/2007 | US20070010494 Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator |
| 01/11/2007 | US20070010493 Phospinite-imidazolines and metal complexes thereof |
| 01/11/2007 | US20070010492 Composition and method for reducing homocysteine caused by drugs containing methyl compounds |
| 01/11/2007 | US20070010491 di-tert-butyl 4-{[1-(3,3-dimethyl-2-oxobutyl)-6-methoxy-1-H-indazole-3-yl]carbonyl}benzylphosphate; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, elevated intraoccular pressure in the eye |
| 01/11/2007 | US20070010490 T-type calcium channel blockers |
| 01/11/2007 | US20070010489 Saquinavir-like, a Lopinavir-like, a Ritonavir-like, a Indinavir-lik, a atazanavir-like, Nelfinavir-like.a Tipranavir-like, a Amprenavir-like, a KNI-like. a cyclic carbonyl-like phosphonate HIV protease inhibitors; drug designing |
| 01/11/2007 | US20070010488 Compounds for modulating cell proliferation |
| 01/11/2007 | US20070010487 Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| 01/11/2007 | US20070010486 Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| 01/11/2007 | US20070010485 Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| 01/11/2007 | US20070010484 Method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration and method for promoting neurogenesis |
| 01/11/2007 | US20070010483 Glucocerebroside treatment of liver disorders |
| 01/11/2007 | US20070010482 de-N-acetylated polysacchride derivative is a polysialic acid heteropolymer comprising residues of N-acetyl sialic acid, de-N-acetyl sialic acid having a free amine, re-N-acylated sialic acid having an amine protecting group other than acetyl group; against Neisseria meningitidis and escherichia coli |
| 01/11/2007 | US20070010481 Solid State Irradiation of Hyaluronan-Based Solid Preparations, Its Derivatives And Mixtures In An Unsaturated Gaseous Atmosphere And Their Use |
| 01/11/2007 | US20070010480 Dietary food items for a weight control or weight loss diet |
| 01/11/2007 | US20070010479 Administering pyrimidine nucleotide precursor where respiratory chain dysfunction is caused by mutation, deletion, or rearrangement of mitochondrial DNA, cytotoxic cancer chemotherapy agents, aging |
| 01/11/2007 | US20070010478 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| 01/11/2007 | US20070010477 Acyl homoserine lactones for inhibition of cell growth |
| 01/11/2007 | US20070010476 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 01/11/2007 | US20070010475 Use of spongosine (2-methoxyadenosein) for the treatment of pain, in particular hyperalgesia |
| 01/11/2007 | US20070010473 Nucleic acid ligands to integrins |
| 01/11/2007 | US20070010472 Oligonucleotide compositions and their use to induce differentiation of cells |
| 01/11/2007 | US20070010470 Immunomodulatory oligonucleotides |
| 01/11/2007 | US20070010467 Targeted double stranded rna mediated cell killing |
| 01/11/2007 | US20070010466 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| 01/11/2007 | US20070010465 Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| 01/11/2007 | US20070010464 Avermectin and praziquantel combination therapy |
| 01/11/2007 | US20070010463 Remedies for diseases caused by strengthened vascular smooth muscle using 14-membered ring macrolid compounds |
| 01/11/2007 | US20070010462 Core 2 GlcNAc-T inhibitors III |
| 01/11/2007 | US20070010461 Core 2 GlcNAc-T inhibitors |
| 01/11/2007 | US20070010460 Treating a subject in need of therapy for a condition involving detrimental activity of the enzyme Core 2 GlcNAc-T(Core 2-N-acetylglucosaminyl transferase) comprising administration of a steroid compound inhibitor thereof; multiple sclerosis; antiinflammatory, anticarcinogenic agents |
| 01/11/2007 | US20070010459 Application of asiatic acid and its derivatives to treat pulmonary fibrosis |
| 01/11/2007 | US20070010458 Drugs for the arthritis treatment |
| 01/11/2007 | US20070010457 Caspase inhibitors and uses thereof |
| 01/11/2007 | US20070010456 Therapeutic agents for low HDL-cholesterolemia |
| 01/11/2007 | US20070010454 Method for treating tumor cells resulting in minimal liver toxicity |
| 01/11/2007 | US20070010453 Prodrugs of GABA analogs, compositions and uses thereof |
| 01/11/2007 | US20070010448 Drug targets in Candida albicans |
| 01/11/2007 | US20070010437 Amino acid based compositions for the treatment of pathological conditions distinguised by insufficient mitochondrial function |
| 01/11/2007 | US20070010435 Method for treating amyloid disease |
| 01/11/2007 | US20070010431 single unit dosage; surfactant and inhibitors of HCV protease or cathepsin; good dissolution for bioabsorption; N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide |
| 01/11/2007 | US20070010429 Phospholipid formulations and uses thereof in lung disease detection and treatment |
| 01/11/2007 | US20070010425 Pharmaceutical compositions and methods for insulin treatment |
| 01/11/2007 | US20070010424 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| 01/11/2007 | US20070010423 Compositions comprising balaglitazone and further antidiabetic compounds |
| 01/11/2007 | US20070010422 Improved bioavailability; for oral and intracolonic administration |
| 01/11/2007 | US20070009971 for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases |
| 01/11/2007 | US20070009967 Methods for shp1 mediated neuroprotection |
| 01/11/2007 | US20070009956 Arginine hydrochloride enhances chaperone-like activity of alpha crystallin |
| 01/11/2007 | US20070009951 Gene expression vaccine |
| 01/11/2007 | US20070009919 Detecting DNA damage by identifying the activation state of Ataxia Telangiectasia-Mutated kinase by determining the phosphorylation state of a specific serine residue; antibodies that recognize the phosphorylation state; drug screening for ATM kinase agonists |
| 01/11/2007 | US20070009619 Neutralizing agent for cavitating toxin |
| 01/11/2007 | US20070009615 Compositions and methods for controlling glucose uptake |
| 01/11/2007 | US20070009614 Composition and method for treating hypertension |
| 01/11/2007 | US20070009612 Method for administering a composition to an animal |
| 01/11/2007 | US20070009611 Treatment of wounds and compositions employed |
| 01/11/2007 | US20070009608 Composition comprising plant and/or fish oils and compounds comprising non-oxidizable fatty acid entities |
| 01/11/2007 | US20070009607 Antibacterial/anti-infalmmatory composition and method |
| 01/11/2007 | US20070009604 Such as proteins or polypeptides via anti-solvent under supercritical conditions; water solubility; Rapid Expansion of Supercritical Solutions or Gas Anti-solvent precipitation |
| 01/11/2007 | US20070009603 Compositions comprising fenofibrate and atorvastatin |
| 01/11/2007 | US20070009601 Composition and method for the treatment of water related ear disorders |
| 01/11/2007 | US20070009600 Antidepressant dosage form |
| 01/11/2007 | US20070009597 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 01/11/2007 | US20070009596 Controlled drug release composition resistant to in vivo mechanic stress |
| 01/11/2007 | US20070009594 Compositions and methods for treatment of cycle-related symptoms |
| 01/11/2007 | US20070009593 Methods of treating cancer |